Potent aryl hydrocarbon receptor (AhR) antagonist (IC50
= 30 nM). Exhibits no AhR agonist-like activity (at concentrations up to 100 μ
M). Inhibits 2,3,7,8-Tetrachlorodibenzo-p
-dioxin (TCDD)-induced AhR-dependent transcription in vitro
and reduces TCDD-induced toxicity in vivo
. Attenuates Th17 differentiation of naive CD4 T cells and promotes expansion of hematopoietic stem cells in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling.
Dubrovska A, Hartung A, Bouchez LC
Br. J. Cancer, 2012;107(1):43-52.
Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.
Kim et al.
Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of TH17 T cells.
Veldhoen et al.
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
Boitano et al.
The citations listed below are publications that use Tocris products. Selected citations for CH 223191 include:
Showing Results 1 - 3 of 3